Rockville, Maryland and Research
Triangle Park, North Carolina
December 4, 2001
Celera Genomics (NYSE:CRA), an Applera Corporation business,
and Paradigm Genetics,
Inc. (Nasdaq:PDGM) today announced a strategic alliance in
agriculture-genomics. Under the terms of the arrangement,
Paradigm will acquire Celera's AgGen plant genomics and
genotyping business and become the exclusive marketing partner
to provide Celera services to the plant-based agriculture
industries. Upon closing of Paradigm's acquisition of the AgGen
genomics and genotyping business, which is subject to customary
conditions, Paradigm's new business unit will be named ParaGen.
As part of the transaction, Celera will receive 422,459 shares
of Paradigm common stock and will share future service revenue
with Paradigm. Financial details of the marketing partnership
were not disclosed.
"We are pleased to enter this relationship with Paradigm
Genetics," said J. Craig Venter, Ph.D., Celera's president and
chief scientific officer. "By working with Paradigm, we should
realize value from services for the plant-based agricultural
industry, while focusing our internal resources on activities
related to Celera's therapeutic discovery and online
businesses."
"This strategic partnership means that Paradigm can now offer
the full array of agricultural genomic technologies, from gene
sequencing, genotyping, and marker-assisted breeding to gene
function discovery, gene expression analysis, phenotypic
analysis and biochemical profiling. In essence, we provide
integrated solutions for plant and microbial-based research and
development projects in agriculture and related industries,"
said John A. Ryals, Ph.D., Paradigm's CEO and President. "This
deal cements our position as a leading player in plant-based
agricultural genomics."
Ken Hunt, Vice President of Agricultural Business Development
for Paradigm, added, "ParaGen will continue to offer to its
current and new customers the excellent service that they have
come to expect from AgGen. By adding Paradigm's core expertise
to the mix, ParaGen can offer expanded services that can be
bundled in any way to meet the needs of each unique customer."
About Celera Genomics
Applera Corporation comprises two operating groups. The Celera
Genomics Group, headquartered in Rockville, MD, is engaged
principally in integrating advanced technologies to create
therapeutic discovery and development capabilities for internal
use and for its customers and collaborators. Celera's businesses
are its online information business and its therapeutics
discovery business. The online information business is a leading
provider of information based on the human genome and other
biological and medical information. Through the therapeutic
discovery business, Celera intends to leverage its genomic and
proteomic capabilities to identify drug targets and diagnostic
marker candidates, and to discover novel therapeutic candidates.
The Applied Biosystems Group (NYSE:ABI) develops and markets
instrument-based systems, reagents, software, and contract
services to the life science industry and research community.
Applied Biosystems is headquartered in Foster City, CA, and
reported sales of $1.6 billion during fiscal 2001. Celera
Diagnostics has been established as a joint venture between
Applied Biosystems and Celera Genomics. This new venture is
focused on discovery, development and commercialization of novel
diagnostic tests. Information about Applera Corporation,
including reports and other information filed by the company
with the Securities and Exchange Commission, is available on the
World Wide Web at www.applera.com, or by telephoning
800.762.6923. Information about Celera is available on the World
Wide Web at www.celera.com.
About Paradigm Genetics, Inc.
Paradigm Genetics, Inc. (Nasdaq: PDGM), headquartered in
Research Triangle Park, NC, is a life sciences company
developing new functional genomics technologies to discover
products for the advancement of agriculture, human health and
nutrition. Paradigm believes that it will be able to use its
proprietary functional genomics and metabolic profiling platform
technologies, GeneFunction Factory(TM), and informatics system
to develop a wide-range of life science products and services.
The company leverages its technology to deliver customized
solutions to agricultural companies. In human health, the
company is working to accelerate drug discovery and development.
And in nutrition, Paradigm is working to discover, develop and
commercialize plant
and microbial-based nutraceutical products. For more
information, visit
www.paradigmgenetics.com.
Company news release
N4011
|